Non-hormonal steroid modulators of NF-kappa beta for treatment of disease
Inventors
McCall, John M. • Hoffman, Eric • Nagaraju, Kanneboyina • Damsker, Jesse
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to compounds and methods which may be useful as treatments of diseases.
Core Innovation
The document describes non-hormonal steroid modulators of NF-kappaB, including targeting the NF-kappaB pathway via I-kappaB kinases (IKKalpha/IKKbeta) to block phosphorylation and degradation of I-kappas. This results in reduced NF-kappaB activation and downstream gene activation mediated by NF-kappaB nuclear localization and DNA binding/gene expression.
The approach is presented as acting through I-kappaB inhibitors and modulation of signaling components in the NF-kappaB pathway, including inhibition of I-kappaB phosphorylation/degradation and the resulting reduction of downstream gene activation. The document also references NF-kappaB-mediated disease contexts involving TNF-alpha and TNF receptor mediated signaling, and includes NEMO (NF-kappaB essential modulator) as part of the NF-kappaB pathway context.
The compounds are described in terms of a broad structural Formula I with extensive R1-R9 substituent definitions, along with specific structural embodiments and images. The document further includes pharmaceutically acceptable salts, prodrugs, pharmaceutical compositions, and combinations, together with formulation and general administration route information for therapeutic use.
Claims Coverage
Two independent claims are provided: clm-00001 and clm-00015. The core inventive approach is focused on treating heart failure by administering a selected compound or pharmaceutically acceptable salts with therapeutically effective daily dosing, and demonstrating functional improvement using ejection fraction and fraction shortening measured by echocardiography.
Administering a selected compound for heart failure treatment
A method of increasing a patient’s ejection fraction and fraction shortening in heart failure by administering, to a patient in need thereof, a therapeutically effective amount between about 2 mg/kg/day and about 30 mg/kg/day of a compound for treating the heart failure chosen from the group consisting of the compound(s) and pharmaceutically acceptable salts thereof.
Oral administration with echocardiography-measured improvement
A method of treating heart failure by oral administration, to a patient in need thereof, of between about 8 mg/kg/day and about 30 mg/kg/day of the compound(s) or a pharmaceutically acceptable salt thereof, where the patient following the administration has improved ejection fraction and fraction shortening as measured by echocardiography.
The independent claims cover heart-failure treatment through administration of a specified compound or pharmaceutically acceptable salt with defined therapeutically effective daily dose ranges, with the later independent claim additionally requiring oral administration and echocardiography-based measurement of improved ejection fraction and fraction shortening.
Stated Advantages
Increased percentage ejection fraction in a patient with heart failure.
Increased percentage fraction shortening in a patient with heart failure.
Improved ejection fraction and fraction shortening as measured by echocardiography.
Documented Applications
Heart failure application is supported by in vivo/figure descriptions indicating improved ejection fraction and fraction shortening, including functional readouts.
Interested in licensing this patent?